Bristol-Myers Squibb Co
BMY50.170USD
+0.950+1.93%
Close 04/30, 16:00（ET）Quotes delayed by 15 min
102.10BMarket Cap
LossP/E TTM
More Details of Bristol-Myers Squibb Co Company
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
Company Info
Company codeBMY
Company nameBristol-Myers Squibb Co
IPO dateJul 05, 1929
Founded at1933
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Number of employees34100
Security typeOrdinary Share
Fiscal year-endJul 05
AddressRoute 206 And Province Line Road
CityPRINCETON
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code08543
Phone16092524621
Websitehttps://www.bms.com
Company codeBMY
IPO dateJul 05, 1929
Founded at1933
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Sandra Leung
Ms. Sandra Leung
Executive Vice President, General Counsel, Member of the Leadership Team
Executive Vice President, General Counsel, Member of the Leadership Team
465.37K
+3.85%
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
125.44K
+19.89%
Mr. Samit Hirawat, M.D.
Mr. Samit Hirawat, M.D.
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
83.51K
+5.36%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, Corporate Affairs, Member of the Leadership Team
Executive Vice President, Corporate Affairs, Member of the Leadership Team
8.32K
+65.81%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Sandra Leung
Ms. Sandra Leung
Executive Vice President, General Counsel, Member of the Leadership Team
Executive Vice President, General Counsel, Member of the Leadership Team
465.37K
+3.85%
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
125.44K
+19.89%
Mr. Samit Hirawat, M.D.
Mr. Samit Hirawat, M.D.
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
Executive Vice President, Chief Medical Officer, Head of Development, Member of the Leadership Team
83.51K
+5.36%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
16.70K
+10.70%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Eliquis
13.33B
27.60%
Opdivo
9.30B
19.26%
Revlimid
5.77B
11.95%
Orencia
3.68B
7.62%
Pomalyst/Imnovid
3.54B
7.34%
Other
12.66B
26.22%
By RegionUSD
Name
Revenue
Proportion
United States
34.10B
70.61%
International
13.20B
27.33%
other
996.00M
2.06%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Eliquis
13.33B
27.60%
Opdivo
9.30B
19.26%
Revlimid
5.77B
11.95%
Orencia
3.68B
7.62%
Pomalyst/Imnovid
3.54B
7.34%
Other
12.66B
26.22%
Shareholder
Update time: Sat, Apr 26
Update time: Sat, Apr 26
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
9.29%
BlackRock Institutional Trust Company, N.A.
4.77%
State Street Global Advisors (US)
4.68%
JP Morgan Asset Management
3.10%
Charles Schwab Investment Management, Inc.
2.96%
Other
75.21%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
9.29%
BlackRock Institutional Trust Company, N.A.
4.77%
State Street Global Advisors (US)
4.68%
JP Morgan Asset Management
3.10%
Charles Schwab Investment Management, Inc.
2.96%
Other
75.21%
Type
Shareholder
Proportion
Investment Advisor
36.67%
Investment Advisor/Hedge Fund
32.60%
Research Firm
2.80%
Pension Fund
2.50%
Bank and Trust
2.26%
Sovereign Wealth Fund
1.84%
Hedge Fund
1.69%
Insurance Company
0.16%
Individual Investor
0.05%
Other
19.42%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
4197
1.65B
81.02%
+17.92M
2024Q4
4261
1.65B
81.14%
+17.04M
2024Q3
4116
1.60B
78.69%
-22.73M
2024Q2
4105
1.59B
78.35%
-83.12M
2024Q1
4118
1.64B
80.97%
+13.32M
2023Q4
4115
1.60B
78.83%
-46.39M
2023Q3
4042
1.63B
77.83%
-55.50M
2023Q2
4082
1.66B
78.77%
-34.93M
2023Q1
4110
1.66B
78.74%
-34.09M
2022Q4
4105
1.66B
77.92%
-72.60M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
189.02M
9.29%
+1.40M
+0.75%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
97.01M
4.77%
-7.46M
-7.14%
Dec 31, 2024
State Street Global Advisors (US)
95.14M
4.68%
+2.25M
+2.42%
Dec 31, 2024
JP Morgan Asset Management
63.10M
3.1%
+12.35M
+24.34%
Dec 31, 2024
Charles Schwab Investment Management, Inc.
60.30M
2.96%
-729.93K
-1.20%
Dec 31, 2024
Capital International Investors
45.87M
2.25%
+3.22M
+7.55%
Dec 31, 2024
Geode Capital Management, L.L.C.
44.39M
2.18%
+1.19M
+2.75%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
35.18M
1.73%
+2.58M
+7.92%
Dec 31, 2024
Columbia Threadneedle Investments (US)
28.50M
1.4%
+12.26M
+75.55%
Dec 31, 2024
Fidelity Management & Research Company LLC
27.55M
1.35%
-9.07M
-24.78%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
First Trust NASDAQ Pharmaceuticals ETF
10.07%
VanEck Morningstar Wide Moat Value ETF
5.06%
Invesco Pharmaceuticals ETF
5.02%
Global X US Cash Flow Kings 100 ETF
4.97%
Invesco S&P Ultra Dividend Revenue ETF
4.9%
VictoryShares Free Cash Flow ETF
4.81%
VanEck Pharmaceutical ETF
4.81%
Cullen Enhanced Equity Income ETF
4.53%
Tema Oncology ETF
4.47%
iShares U.S. Pharmaceuticals ETF
4.38%
View more
First Trust NASDAQ Pharmaceuticals ETF
Proportion10.07%
VanEck Morningstar Wide Moat Value ETF
Proportion5.06%
Invesco Pharmaceuticals ETF
Proportion5.02%
Global X US Cash Flow Kings 100 ETF
Proportion4.97%
Invesco S&P Ultra Dividend Revenue ETF
Proportion4.9%
VictoryShares Free Cash Flow ETF
Proportion4.81%
VanEck Pharmaceutical ETF
Proportion4.81%
Cullen Enhanced Equity Income ETF
Proportion4.53%
Tema Oncology ETF
Proportion4.47%
iShares U.S. Pharmaceuticals ETF
Proportion4.38%
Dividend
A total of
22.71B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
Jun 14, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option
Jul 07, 2023
Aug 01, 2023
Jul 06, 2023
Mar 03, 2023
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023
Apr 10, 2023
May 01, 2023
Apr 06, 2023
Dec 08, 2022
BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023
Jan 06, 2023
Feb 01, 2023
Jan 05, 2023
Sep 14, 2022
BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022
Oct 07, 2022
Nov 01, 2022
Oct 06, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data